Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HHS and 80,000+ other tickers.
See exactly how HHS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HHS and 80,000+ other tickers.
Harte Hanks, Inc. is an established global firm specializing in customer experience solutions, operating both domestically and internationally. Its business is structured around three primary divisions: Marketing Services, Customer Care, and Fulfillment & Logistics Services. Within Marketing Services, the company offers strategic guidance to clients, aiding in the design and execution of integrated omni-channel marketing initiatives. This comprehensive offering includes audience identification, detailed profiling, segmentation, prioritization, predictive analytics, and sophisticated data…
The Department of Health and Human Services is planning to appoint deputy commissioners for technology and drugs at the FDA, creating new roles at the agency, CNBC has learned. Like existing deputy commissioner roles, the two new positions would report into Trump's pick for FDA commissioner, Heidi Overton, who still needs to be confirmed by the Senate.
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - CHMI, VREX, HHS and ARX PR Newswire
Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
MILWAUKEE, Aug. 14, 2026 /PRNewswire/ -- Ademi LLP is investigating Harte Hanks (NASDAQ: HHS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Star Equity. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.